Liana Adam

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Focus on bladder cancer
    Colin P N Dinney
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX USA
    Cancer Cell 6:111-6. 2004
  2. ncbi Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer
    Liana Adam
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 177:1900-6. 2007
  3. ncbi miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy
    Liana Adam
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:5060-72. 2009
  4. ncbi Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells
    Peter C Black
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:1478-86. 2008
  5. doi Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
    David J McConkey
    Department of Urology, U T M D Anderson Cancer Center, P O Box 1373, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Metastasis Rev 28:335-44. 2009
  6. ncbi Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells
    Wassim Kassouf
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:10524-35. 2005
  7. pmc Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase
    Poonam R Molli
    Department of Molecular and Cellular Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 14:6161-70. 2008
  8. ncbi Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression
    Marissa Shrader
    Departments of Cancer Biology and Urology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:1430-5. 2007
  9. ncbi The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells
    Zhibo Yang
    Department of Molecular and Cellular Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:658-67. 2004
  10. ncbi Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein
    William F Benedict
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Ther 10:525-32. 2004

Collaborators

Detail Information

Publications28

  1. ncbi Focus on bladder cancer
    Colin P N Dinney
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX USA
    Cancer Cell 6:111-6. 2004
  2. ncbi Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer
    Liana Adam
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 177:1900-6. 2007
    ..We determined whether the inhibition of angiogenesis might contribute to the antitumor effect...
  3. ncbi miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy
    Liana Adam
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:5060-72. 2009
    ..The aims of this study were to determine the potential role of microRNAs (miRNA) in controlling EMT and the role of EMT in inducing the sensitivity of human bladder cancer cells to the inhibitory effects of the anti-EGFR therapy...
  4. ncbi Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells
    Peter C Black
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:1478-86. 2008
    ..The aim of this study was to define molecular markers of response to cetuximab therapy in a panel of urothelial carcinoma cell lines...
  5. doi Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
    David J McConkey
    Department of Urology, U T M D Anderson Cancer Center, P O Box 1373, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Metastasis Rev 28:335-44. 2009
    ..The results suggest that EMT coordinately regulates drug resistance and muscle invasion/metastasis in urothelial cancer and is a dominant feature of overall cancer biology...
  6. ncbi Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells
    Wassim Kassouf
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:10524-35. 2005
    ....
  7. pmc Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase
    Poonam R Molli
    Department of Molecular and Cellular Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 14:6161-70. 2008
    ....
  8. ncbi Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression
    Marissa Shrader
    Departments of Cancer Biology and Urology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:1430-5. 2007
    ....
  9. ncbi The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells
    Zhibo Yang
    Department of Molecular and Cellular Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:658-67. 2004
    ....
  10. ncbi Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein
    William F Benedict
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Ther 10:525-32. 2004
    ..These findings demonstrate that Ad-IFNalpha can overcome resistance to IFN-alpha protein both in vitro and in vivo and support evaluation of intravesical Ad-IFNalpha/Syn3 for the treatment of superficial bladder cancer...
  11. doi Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer
    Peter C Black
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 185:693-700. 2011
    ..We determined whether there is functional crosstalk between epidermal growth factor receptor and platelet-derived growth factor receptor-β, and how this regulates biological functions in bladder cancer cases...
  12. ncbi Molecular correlates of gefitinib responsiveness in human bladder cancer cells
    Marissa Shrader
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Unit 173, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 6:277-85. 2007
    ..However, comparing levels of p27(Kip1) or DNA synthesis before and after gefitinib exposure does identify the drug-sensitive cells...
  13. ncbi A miRNA signature associated with human metastatic medullary thyroid carcinoma
    Libero Santarpia
    Departments of Endocrine Neoplasia and Hormonal Disorders Experimental Therapeutics Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA Department of Oncology, The University of Naples, Naples, Italy Department of Pathology, Centro Oncologico Fiorentino, Sesto Fiorentino, Florence, Italy Verna and Marrs McLean Department of Biochemistry and Molecular Biology Baylor College of Medicine, Houston, Texas, USA Department of Oncology, Istituto Toscano Tumori, Hospital of Prato, Prato, Italy Department of Gynecologic Oncology, Center for RNA Interference and Non coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Endocrinology, University of Messina, Messina, Italy Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA Department of Internal Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Endocr Relat Cancer 20:809-23. 2013
    ..Our data identify a robust miRNA signature associated with metastatic MTC and distinct biological processes, e.g., TGFβ signalling pathway, providing new potential insights into the mechanisms of MTC metastasis...
  14. ncbi Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer
    Wassim Kassouf
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Urol 176:787-92. 2006
    ..We determined the sequence specific efficacy of gefitinib and docetaxel treatment for bladder cancer. This combination was selected because it is currently under study in a phase II clinical trial...
  15. ncbi Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215
    Ratna K Vadlamudi
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    FEBS Lett 543:76-80. 2003
    ..These findings suggest that HER2/HRG influence metastasis of breast cancer cells through a novel signaling pathway involving phosphorylation of FAK tyrosine 861 via activation of c-Src tyrosine 215...
  16. ncbi Plasma microRNA profiles for bladder cancer detection
    Liana Adam
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 31:1701-8. 2013
    ..Plasma miRNAs are promising biomarkers that have yet to be rigorously investigated in BC...
  17. pmc p63 expression defines a lethal subset of muscle-invasive bladder cancers
    Woonyoung Choi
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e30206. 2012
    ..Previous studies demonstrated that p63 is downregulated in muscle-invasive bladder cancers, but the relationship between p63 expression and survival is not clear...
  18. ncbi Clinical applications for targeted therapy in bladder cancer
    Liana Adam
    The University of Texas M D Anderson Cancer Center, Department of Urology, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA
    Urol Clin North Am 32:239-46, vii. 2005
    ....
  19. ncbi Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy
    Kelly N Blehm
    Department of Cancer Biology, Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4671-7. 2006
    ..The focus of this study was to determine if these alterations are present within the tyrosine kinase and ligand-binding domain of EGFR in urothelial carcinoma...
  20. doi The stabilization and targeting of surfactant-synthesized gold nanorods
    Betty C Rostro-Kohanloo
    Department of Physics and Astronomy, Rice University, Houston, TX 77005, USA
    Nanotechnology 20:434005. 2009
    ..This covalent strategy should be generally applicable to other biomedical applications of gold nanorods as well as other gold nanoparticles synthesized with CTAB...
  21. ncbi Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2
    Ratna K Vadlamudi
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Cell Physiol 190:189-99. 2002
    ..Our results suggest that HRG differentially regulates signaling from focal adhesion complexes through selective phosphorylation and dephosphorylation and that tyrosine phosphatase SHP-2 has a role in the HRG signaling...
  22. ncbi Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1
    Ratna K Vadlamudi
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Nat Cell Biol 4:681-90. 2002
    ....
  23. ncbi A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm
    Rakesh Kumar
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Nature 418:654-7. 2002
    ..MTA1s expression is increased in human breast tumours with no or low nuclear ER. The regulation of the cellular localization of ER by MTA1s represents a mechanism for redirecting nuclear receptor signalling by nuclear exclusion...
  24. pmc p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells
    Feng Li
    The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    EMBO Rep 3:767-73. 2002
    ..Together, these results suggest for the first time that Pak1 interacts with and phosphorylates histone H3 and may thus influence the Pak1-histone H3 pathway, which in turn may influence mitotic events in breast cancer cells...
  25. ncbi Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
    Wassim Kassouf
    Division of Urology, McGill University Health Center, Montreal, Quebec, Canada
    J Urol 180:1146-53. 2008
    ..We investigated the relationship between the modulation of vascular endothelial growth factor (Santa Cruz Biotechnology, Santa Cruz, California) expression and the biological efficacy of gefitinib for bladder cancer...
  26. ncbi Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation
    Robert X D Song
    Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA
    Mol Endocrinol 16:116-27. 2002
    ..The E2-induced morphological changes were prevented by antiestrogen. Together our results demonstrate that ERalpha can mediate the rapid effects of E2 on Shc, MAPK, Elk-1, and morphological changes in breast cancer cells..
  27. ncbi The role of mitogen-activated protein (MAP) kinase in breast cancer
    Richard J Santen
    Department of Medicine, Division of Endocrinology, University of Virginia Health System, P O Box 800379, Charlottesville, VA 22908, USA
    J Steroid Biochem Mol Biol 80:239-56. 2002
    ..Additional studies are now needed to determine the precise relationship between MAP kinase activation and tumor proliferation, apoptosis, and degree of invasiveness as well as on disease free and overall survival...
  28. pmc Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer
    Wassim Kassouf
    Division of Urology, McGill University Health Center, Montreal, Quebec, Canada
    J Urol 179:353-8. 2008
    ..We examined the correlation of ErbB family receptor expression with the progression of urothelial carcinoma and survival...